Skip to main content

Advertisement

SpringerLink
Log in

Efficacy and safety of odanacatib treatment for patients with osteoporosis: a meta-analysis

  • Original Article
  • Published:
Journal of Bone and Mineral Metabolism Aims and scope Submit manuscript

Abstract

The aim of this study was to evaluate the efficacy and safety of odanacatib (ODN) for the treatment of osteoporosis, using data in studies reported in the literature. We performed a literature search to compare the outcomes of applications of once-weekly ODN 50 mg and control. The outcomes of osteoporosis evaluated include primary outcome as bone mineral density (BMD) at different skeletal sites, and secondary outcomes, including adverse events (AEs), such as incidence of skin AEs, fracture, and serious adverse events (SAEs). Four trials were included. Mean difference (95 % CI) of lumbar spine BMD was 3.41 (1.57–5.24) at 12 months and 4.89 (2.72–7.05) at 24 months; mean difference (95 % CI) of femoral neck BMD was 1.90 (0.73–3.08) at 12 months and 3.85 (2.55–5.15) at 24 months; mean difference (95 % CI) of total hip BMD was 2.65 (1.20–4.09) at 12 months and 3.70 (1.76–5.64) at 24 months; risk ratio (95 % CI) of AEs was 0.98 (0.91–1.07); risk ratio (95 % CI) of SAEs was 1.11 (0.72–1.72); risk ratio (95 % CI) of skin AEs was 0.92 (0.63–1.35); and risk ratio (95 % CI) of fracture was 0.34 (0.16–0.70). In this study, application of 50 mg ODN produced significantly greater BMD increases and lower fracture incidence than that of the control. In addition, ODN was generally well tolerated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. National Osteoporosis Foundation (2010) Clinician’s guide to prevention and treatment of osteoporosis. Available at: http://www.nof.org/sites/default/files/pdfs/NOF_ClinicianGuide2009_v7pdf

  2. Johnell O, Kanis JA (2006) An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 17:1726–1733

    Article  CAS  PubMed  Google Scholar 

  3. Simonelli C, Burke MS (2006) Less frequent dosing of bisphosphonates in osteoporosis: focus on ibandronate. Curr Med Res Opin 22:1101–1108

    Article  CAS  PubMed  Google Scholar 

  4. Cusick T, Chen CM, Pennypacker BL, Pickarski M, Kimmel DB et al (2012) Odanacatib treatment increases hip bone mass and cortical thickness by preserving endocortical bone formation and stimulating periosteal bone formation in the ovariectomized adult rhesus monkey. J Bone Miner Res 27:524–537

    Article  CAS  PubMed  Google Scholar 

  5. Masarachia PJ, Pennypacker BL, Pickarski M, Scott KR, Wesolowski GA et al (2012) Odanacatib reduces bone turnover and increases bone mass in the lumbar spine of skeletally mature ovariectomized rhesus monkeys. J Bone Miner Res 27:509–523

    Article  CAS  PubMed  Google Scholar 

  6. Bone HG, McClung MR, Roux C, Recker RR, Eisman JA et al (2010) Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density. J Bone Miner Res 25:937–947

    PubMed  Google Scholar 

  7. Brixen K, Chapurlat R, Cheung AM, Keaveny TM, Fuerst T et al (2013) Bone density, turnover, and estimated strength in postmenopausal women treated with odanacatib: a randomized trial. J Clin Endocrinol Metab 98:571–580

    Article  CAS  PubMed  Google Scholar 

  8. Nakamura T, Shiraki M, Fukunaga M, Tomomitsu T, Santora AC et al (2014) Effect of the cathepsin K inhibitor odanacatib administered once weekly on bone mineral density in Japanese patients with osteoporosis—a double-blind, randomized, dose-finding study. Osteoporos Int 25:367–376

    Article  CAS  PubMed  Google Scholar 

  9. Bonnick S, De Villiers T, Odio A, Palacios S, Chapurlat R et al (2013) Effects of odanacatib on BMD and safety in the treatment of osteoporosis in postmenopausal women previously treated with alendronate: a randomized placebo-controlled trial. J Clin Endocrinol Metab 98:4727–4735

    Article  CAS  PubMed  Google Scholar 

  10. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 6:e1000100

    Article  PubMed Central  PubMed  Google Scholar 

  11. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D et al (2011) The Cochrane collaboration’s tool for assessing risk of bias in randomised trials. BMJ 343:d5928

    Article  PubMed Central  PubMed  Google Scholar 

  12. Higgins JP, Green S (eds) (2006) Cochrane handbook for systematic reviews of interventions 4.2.6. In: The Cochrane Library, Issue 4. Wiley, Chichester (updated September 2006)

  13. Bonnick S, Saag KG, Kiel DP, McClung M, Hochberg M et al (2006) Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years. J Clin Endocrinol Metab 91:2631–2637

    Article  CAS  PubMed  Google Scholar 

  14. Reid DM, Hosking D, Kendler D, Brandi ML, Wark JD et al (2008) A comparison of the effect of alendronate and risedronate on bone mineral density in postmenopausal women with osteoporosis: 24-month results from FACTS-international. Int J Clin Pract 62:575–584

    Article  CAS  PubMed  Google Scholar 

  15. Schnitzer T, Bone HG, Crepaldi G, Adami S, McClung M et al (2000) Therapeutic equivalence of alendronate 70 mg once weekly and alendronate 10 mg daily in the treatment of osteoporosis. Aging Clin Exp Res 12:1–12

    Article  CAS  Google Scholar 

  16. Ettinger B, San Martin J, Crans G, Pavo I (2004) Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 19:745–751

    Article  CAS  PubMed  Google Scholar 

  17. Miller PD, Delmas PD, Lindsay R, Watts NB, Luckey M et al (2008) Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate. J Clin Endocrinol Metab 93:3785–3793

    Article  CAS  PubMed  Google Scholar 

  18. Boonen S, Marin F, Obermayer-Pietsch B, Simões ME, Barker C et al (2008) Effects of prior antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 93:852–860

    Article  CAS  PubMed  Google Scholar 

  19. Cosman F, Wermers RA, Recknor C, Mauck KF, Xie L et al (2009) Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent. J Clin Endocrinol Metab 94:3772–3780

    Article  CAS  PubMed  Google Scholar 

  20. Eisman JA, Bone HG, Hosking DJ, McClung MR, Reid IR et al (2011) Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect. J Bone Miner Res 26:242–251

    Article  CAS  PubMed  Google Scholar 

  21. Baron R, Ferrari S, Russell RG (2011) Denosumab and bisphosphonates: different mechanisms of action and effects. Bone 48:677–692

    Article  CAS  PubMed  Google Scholar 

  22. Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756–765

    Article  CAS  PubMed  Google Scholar 

  23. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE et al (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture intervention trial research group. Lancet 348:1535–1541

    Article  CAS  PubMed  Google Scholar 

  24. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T et al (1999) Effects of risedronate treatment on vertebral and non vertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA 282:1344–1352

    Article  CAS  PubMed  Google Scholar 

  25. Miller PD, Recker RR, Reginster JY, Riis BJ, Czerwinski E et al (2012) Efficacy of monthly oral ibandronate is sustained over 5 years: the MOBILE long-term extension study. Osteoporos Int 23:1747–1756

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

There are no identified conflicts of interest with any of the authors.

Author information

Authors and Affiliations

  1. Department of Orthopaedic Surgery, Shengjing Hospital, China Medical University, 36 Sanhao Road, Shenyang, 110004, China

    Shi Feng, Zhicheng Luo & Da Liu

Authors
  1. Shi Feng
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zhicheng Luo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Da Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Da Liu.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Feng, S., Luo, Z. & Liu, D. Efficacy and safety of odanacatib treatment for patients with osteoporosis: a meta-analysis. J Bone Miner Metab 33, 448–454 (2015). https://doi.org/10.1007/s00774-014-0609-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00774-014-0609-3

Keywords

Search

Navigation